Sasanlimab Prolongs EFS When Combined with BCG Induction and Maintenance in Patients with BCG-naive High-Risk NMIBC By Ogkologos - July 22, 2025 721 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CREST study Source RELATED ARTICLESMORE FROM AUTHOR Ovarian Reserve Better Indicator of Adjuvant Chemotherapy Benefit than Self-Reported Menopause Status, Age, or Other Hormone Levels Immune-Modulating SBRT Plus Anti-PD-L1 May Convert Immune-Cold ER-positive, HER2-negative EBC Into More Inflamed Tumours and Improve Response EMA Recommends Extension of Therapeutic Indications for Serplulimab MOST POPULAR PAXG Significantly Improves EFS Compared with mFOLFIRINOX in Patients with Resectable... February 9, 2026 Deputy Spends His Days Off Teaching Life Skills To Young Boys... December 26, 2021 2022 ASCO Annual Meeting: Advances in Treating Breast Cancer, Colorectal Cancer, Ewing... June 5, 2022 Treatment with a Hypomethylating Agent Can Activate or Up-regulate Oncogenes June 3, 2022 Load more HOT NEWS Lazertinib Demonstrates Significant Efficacy Improvement Compared with Gefitinib in the First-Line... EMA Recommends Granting a Marketing Authorisation for Biosimilar Bevacizumab Hospice Nurse Fired from Job After Being Diagnosed with Breast Cancer An integral part of research
